Methotrexate And The Treatment Of Rheumatoid Arthritis

Conference name: 2nd International conference on pathology

Short name: Pathology 2019

Venue : Paris,France | July 5-6,2019

URL: https://bit.ly/2GS09CI

Methotrexate is regarded as the gold standard in rheumatology, due to its efficacy and safety profile for a long period of time. From German register analyses it is known that methotrexate not only demonstrates the highest therapy continuity in RA, but that 60% of adults and 46% of all juvenile idiopathic arthritis (JIA) patients are treated with this drug.

In RA the potential for MTX is far from exhausted, and its key position as the first-line therapeutic agent in the current guidelines are based on its reliable effectiveness in combination therapies and its predominantly manageable side effects. However, a decisive factor for patient compliance is the form of application, where in subcutaneous application of methotrexate, RA patients prefer the Medac autoinjector over the pre-filled syringe.

To know more about Pathology and its Applications do attend International Conference on Pathology 2019 http://pathology.alliedacademies.com/

Contact
KRISTIE NOVA
Program Director | PATHOLOGY 2019
Phone: (44) 20 3769 1755
Email: pathology(at)alliedannualsummit(dot)com